BIOMAT Database Logo BIOMAT Database Logo

[Drug administration schedule of anti-ulcer agents to prevent recurrence of peptic ulcer; intermittent and long-term administration]. 1988

H Sakai, and H Oka, and M Sakaguchi

UI MeSH Term Description Entries
D010437 Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastroduodenal Ulcer,Marginal Ulcer,Gastroduodenal Ulcers,Marginal Ulcers,Peptic Ulcers,Ulcer, Gastroduodenal,Ulcer, Marginal,Ulcer, Peptic,Ulcers, Gastroduodenal,Ulcers, Marginal,Ulcers, Peptic
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Sakai, and H Oka, and M Sakaguchi
[Drug administration schedule of anti-ulcer agents to prevent recurrence of peptic ulcer; problems on standardization of the appropriate time for the withdrawal of anti-ulcer agents].
January 1988, Nihon rinsho. Japanese journal of clinical medicine,
H Sakai, and H Oka, and M Sakaguchi
[Drug administration schedule of anti-ulcer agents to prevent recurrence of peptic ulcer; administration of synergistic drugs for protective factors in peptic ulcer--criteria of drug selection according to clinical symptoms and administration methods].
January 1988, Nihon rinsho. Japanese journal of clinical medicine,
H Sakai, and H Oka, and M Sakaguchi
[Drug administration schedule of anti-ulcer agents to prevent recurrence of peptic ulcer; combination therapy of inhibitors of attacking factors and synergistic drugs for protective factors in peptic ulcer--selection of drug combinations and clinical efficacy].
January 1988, Nihon rinsho. Japanese journal of clinical medicine,
H Sakai, and H Oka, and M Sakaguchi
[Long-term drug therapy of peptic ulcer].
November 1982, Deutsche medizinische Wochenschrift (1946),
H Sakai, and H Oka, and M Sakaguchi
Long-term drug therapy in peptic ulcer.
December 1961, The American journal of gastroenterology,
H Sakai, and H Oka, and M Sakaguchi
Management of acute peptic ulcer; measures to prevent recurrence.
June 1959, Postgraduate medicine,
H Sakai, and H Oka, and M Sakaguchi
[Anti-recurrence treatment of peptic ulcer].
January 1974, Terapevticheskii arkhiv,
H Sakai, and H Oka, and M Sakaguchi
Drug therapy for preventing peptic ulcer recurrence.
November 1986, American family physician,
H Sakai, and H Oka, and M Sakaguchi
[Long-term drug therapy of peptic ulcer disease. A current review of the status of various anti-ulcer drugs].
December 1986, Fortschritte der Medizin,
H Sakai, and H Oka, and M Sakaguchi
[Long-term therapy of peptic ulcer].
March 1992, Zeitschrift fur arztliche Fortbildung,
Copied contents to your clipboard!